Innovative Vaccine Technologies Arcturus Therapeutics has developed the world’s first approved self-amplifying mRNA COVID vaccine using their proprietary STARR® mRNA technology and LUNAR® delivery platform. This positions the company as a leader in next-generation RNA vaccine development, creating opportunities for collaborations and supply chain partnerships in vaccine manufacturing and distribution.

Expanding Therapeutic Pipeline The company's pipeline includes RNA therapeutics targeting rare liver and respiratory diseases such as OTC deficiency and cystic fibrosis, as well as vaccine programs for SARS-CoV-2 and influenza. This diverse portfolio offers prospects for joint ventures, licensing, or technology licensing to support expanding indications across infectious and rare disease markets.

Global Collaborative Presence Arcturus has established strategic global collaborations, including a joint venture in Japan and partnerships with CSL Seqirus, which could facilitate entry into new geographic markets and local manufacturing opportunities, expanding the reach of their innovative mRNA solutions.

Strong Patent Portfolio With over 500 patents and applications worldwide, Arcturus has a substantial intellectual property base that can be leveraged for licensing opportunities or to establish proprietary manufacturing agreements, helping to secure competitive advantages and revenue streams.

Growth and Investment Potential As a company generating between $100 million and $250 million in revenue with ongoing funding and high-profile leadership appointments like Moncef Slaoui, Arcturus shows strong growth prospects and may be open to strategic investments, partnerships, or supply agreements to accelerate their development and commercialization activities.